How to Achieve Veterinary Drug Registration in China: Guide for Foreign Companies
Overview
China’s veterinary drug market is one of the largest in the world, valued at over RMB 60 billion and growing steadily alongside the country’s expanding livestock, aquaculture, and pet care sectors. For foreign pharmaceutical companies, achieving veterinary drug registration in China represents both a significant opportunity and a formidable regulatory challenge. The approval pathway is managed primarily by the Ministry of Agriculture and Rural Affairs (MOA) through its Veterinary Drug Evaluation Center, with additional oversight from the National Medical Products Administration (NMPA) for certain product categories.
This guide provides a comprehensive overview of the veterinary drug registration process in China, including classification systems, application pathways, clinical trial requirements, dossier preparation, and post-approval obligations for foreign companies.
1. The Regulatory Landscape
1.1 Key Legislation
The primary legal framework for veterinary drug registration in China includes:
- Regulations on the Administration of Veterinary Drugs (State Council Decree No. 404, revised 2020) — the foundational regulation governing all veterinary drugs in China
- Measures for the Registration of Veterinary Drugs (MOA Decree No. 52, 2022 revision) — detailed procedural rules for registration
- Veterinary Pharmacopoeia of the People’s Republic of China (2020 edition) — quality standards, test methods, and monograph specifications
- Catalog of Veterinary Drugs for the Prevention and Treatment of Animal Diseases — the positive list of approved veterinary drugs
- Good Manufacturing Practice for Veterinary Drugs (兽药GMP) — manufacturing quality standards
- Good Clinical Practice for Veterinary Drugs (兽药GCP) — clinical trial standards
- Good Laboratory Practice for Veterinary Drugs (兽药GLP) — non-clinical safety testing standards
1.2 Regulatory Bodies
- Ministry of Agriculture and Rural Affairs (MOA) — the primary authority for veterinary drug registration, approval, and post-market surveillance
- China Institute of Veterinary Drug Control (中国兽医药品监察所) — technical evaluation, quality testing, and standard setting
- National Medical Products Administration (NMPA) — involved for veterinary drugs with biological components or combination products with human drug implications
- Provincial Agriculture and Rural Bureaus — local GMP inspection and enforcement
2. Veterinary Drug Classification in China
Understanding the classification of your product is essential, as it determines the registration pathway, data requirements, and timeline.
2.1 By Category
| Category | Description | Examples |
|---|---|---|
| Chemical veterinary drugs | Synthetically produced active pharmaceutical ingredients | Antibiotics, antiparasitics, anti-inflammatories |
| Traditional Chinese veterinary medicine | Herbal and botanical preparations for animals | Herbal digestive aids, immune modulators |
| Biological veterinary products | Vaccines, antigens, antisera, and diagnostic reagents | Rabies vaccine, canine distemper vaccine |
| Antimicrobial veterinary drugs | Subject to special restrictions under China’s antimicrobial resistance (AMR) action plan | Colistin, enrofloxacin, tylosin |
2.2 By Registration Class (for Chemical Drugs)
The MOA classifies veterinary chemical drugs into five registration classes:
- Class 1: New molecular entities never approved in China or anywhere else globally — requires complete non-clinical and clinical data
- Class 2: New formulations or combinations of already approved active ingredients — reduced data requirements
- Class 3: Generic veterinary drugs that are not on the Chinese pharmacopeia but approved in other countries — requires bioequivalence data
- Class 4: Generic veterinary drugs listed in the Chinese Veterinary Pharmacopoeia — abbreviated registration pathway
- Class 5: Already approved foreign veterinary drugs imported into China — most common pathway for foreign companies, requires bridging studies and local clinical data
Most foreign veterinary drug companies entering China for the first time will apply under Class 5 (import registration).
3. The Registration Process Step-by-Step
The complete registration process typically takes 2 to 5 years from initial preparation to final approval, depending on product class and the completeness of submitted data.
Phase 1: Pre-Registration Preparation (3-6 months)
- Regulatory strategy development: Determine the appropriate registration classification and identify data gaps
- Engage a China-based regulatory agent: Foreign companies must appoint a Chinese entity as their registration agent — this can be a subsidiary, a local partner, or a professional regulatory consultancy
- Establish a China-based manufacturer or importer entity: A registered Chinese legal entity is required as the drug registration holder or importer
- Product testing according to Chinese Pharmacopoeia: Arrange for testing of the product by a CNAS-accredited Chinese laboratory against Chinese pharmacopeia standards
- Pre-submission communication with MOA: Seek preliminary guidance from MOA on specific data requirements for your product type
Phase 2: Non-Clinical Studies (if applicable, 6-18 months)
For Class 1 and some Class 5 products, non-clinical studies must be conducted at GLP-certified facilities:
- Pharmacodynamics studies
- Pharmacokinetics studies
- Toxicology studies (acute, subchronic, chronic)
- Local tolerance studies
- Environmental impact assessment (China requires specific ecotoxicity data)
- Residue depletion studies (for food-producing animals)
- Withdrawal period determination
Note: China does not automatically accept foreign GLP data. Bridging studies or local GLP-confirmatory studies may be required.
Phase 3: Clinical Trials (12-24 months)
Clinical trials must be conducted at MOA-approved GCP-certified clinical trial centers in China. Requirements vary by product class:
- Class 5 (import registration): Typically requires at least one Phase III clinical trial conducted in China using locally sourced target animals (dogs, cats, livestock, or poultry as applicable)
- Target animal safety (TAS) study: Required for most drugs to demonstrate safety in the target species under Chinese conditions
- Field efficacy study: Demonstrates that the drug is effective under Chinese husbandry and disease conditions
- Clinical trial protocol review: Must be submitted and approved by the MOA before commencing any trial
Phase 4: Dossier Submission and Review (12-18 months)
The registration dossier (referred to as the “Veterinary Drug Registration Application Dossier”) is submitted through the China-based agent to the MOA’s Veterinary Drug Evaluation Center. The dossier includes:
- Part 1: Administrative information — application forms, power of attorney, manufacturing authorization, GMP certificates, free sale certificate
- Part 2: Drug substance documentation — synthesis/manufacturing process, characterization, impurity profile
- Part 3: Drug product documentation — formulation, manufacturing process, specifications, stability data
- Part 4: Non-clinical study reports — pharmacology, toxicology, residue studies
- Part 5: Clinical study reports — target animal safety, field efficacy, and any additional studies
- Part 6: Quality control documentation — analytical methods, validation, batch analysis
All documents must be translated into Chinese. The review process involves:
- Formal review — completeness check (1-2 months)
- Technical review — scientific evaluation by MOA experts (6-12 months)
- Request for supplementary information (if needed) — allow 3-6 months for response
- Quality testing — sample testing by China Institute of Veterinary Drug Control (2-3 months)
- GMP inspection — on-site inspection of the overseas manufacturing facility (if required, 1-2 months for inspection plus preparation)
Phase 5: Approval and Certificate Issuance
- Upon approval, MOA issues the Veterinary Drug Registration Certificate (兽药注册证书)
- Certificate is valid for 5 years
- Product is added to the official catalog of approved veterinary drugs
- Certificate holder (China entity) is responsible for post-approval obligations
4. Estimated Timelines and Costs
| Phase | Duration | Estimated Cost (USD) |
|---|---|---|
| Regulatory strategy and agent engagement | 3-6 months | $30,000 – $80,000 |
| China entity setup (if not already established) | 3-6 months | $15,000 – $30,000 |
| Non-clinical studies (if required) | 6-18 months | $200,000 – $500,000 |
| Clinical trials in China | 12-24 months | $300,000 – $1,000,000 |
| Dossier compilation and translation | 3-6 months | $50,000 – $150,000 |
| MOA review and evaluation | 12-18 months | $30,000 – $80,000 |
| GMP inspection (if required) | 2-4 months | $50,000 – $100,000 |
| Total (Class 5 import) | 3-5 years | $675,000 – $1,940,000 |
5. Special Considerations for Pet Pharmaceuticals
The pet pharmaceutical market in China (drugs for dogs, cats, and companion animals) has specific characteristics that differ from livestock-focused veterinary drugs:
5.1 Market Demand Drivers
- Rising pet ownership and willingness to spend on pet healthcare
- Increasing prevalence of chronic conditions (allergies, arthritis, obesity) in aging pet populations
- Growing adoption of pet insurance, which expands access to veterinary pharmaceuticals
- Demand for convenient dosage forms (chewable tablets, spot-on treatments, long-acting injections)
5.2 Regulatory Considerations
- China recognizes companion animal-specific drugs as a distinct category with potentially different evaluation criteria
- Residue studies are not required for pet-only drugs (since companion animals are not food-producing)
- However, safety data requirements may be more stringent as pets live in close contact with humans
- Import registration (Class 5) is the most common pathway for foreign pet pharmaceutical products
6. Post-Approval Obligations
Once a veterinary drug registration certificate is granted, the certificate holder (the China-based entity) has ongoing obligations:
- Adverse drug reaction (ADR) reporting: Establish an ADR monitoring system and report to MOA quarterly and within 15 days for serious ADRs
- Renewal: Submit renewal application at least 6 months before certificate expiry, including post-market safety and efficacy data
- Variation management: Any changes to the manufacturing process, formulation, specification, packaging, or labeling require MOA approval. Variations are classified as major, moderate, or minor, with corresponding review timelines
- Annual quality summary: Submit an annual product quality report to MOA
- GMP maintenance: Maintain GMP compliance and undergo periodic inspections
- Import monitoring: Coordinate with GACC for customs clearance of each batch — each batch requires testing and release by a designated veterinary drug testing laboratory
7. Strategic Recommendations for Foreign Companies
- Start early with trademark registration: Register your trademark in China (Classes 5 and 31) at least 12-18 months before submitting the drug registration application. Trademark squatting is common in China’s pharmaceutical sector
- Build local regulatory expertise: Hire or contract with China-based regulatory affairs professionals who have specific veterinary drug registration experience. The regulatory landscape changes frequently, and local expertise is invaluable
- Engage a strong Chinese partner: For Class 5 import registration, consider partnering with an established Chinese veterinary pharmaceutical company that can serve as both your registration agent and distribution partner
- Plan for data localization: China increasingly requires clinical data generated from Chinese populations. Budget adequately for local clinical trials
- Consider generics first: If your company has Class 4 generic veterinary drugs (listed in the Chinese Pharmacopoeia), these can provide a faster and less expensive market entry pathway while you prepare for Class 5 branded product registration
- Monitor the priority review pathway: MOA offers accelerated review for certain veterinary drugs — including those targeting zoonotic diseases, drugs with urgent animal health needs, and innovative products with significant therapeutic advantages
8. Frequently Asked Questions
Q: Can I use clinical data generated outside China for the Chinese registration?
A: For Class 5 import registration, foreign clinical data is accepted as supporting evidence, but at least one Phase III clinical trial conducted in China is typically required. The MOA may accept foreign data if the study was conducted according to ICH VICH guidelines and the data is accompanied by a comprehensive bridging report.
Q: What is the validity period of the Veterinary Drug Registration Certificate?
A: The certificate is valid for 5 years. Renewal requires submission of post-marketing safety and efficacy data, quality summary, and updated manufacturing documentation at least 6 months before expiry.
Q: Do I need a separate registration for different strengths or dosage forms?
A: Yes. Each strength, dosage form, and formulation variant requires a separate registration application. However, related products can sometimes be bundled under a single dossier with accompanying justification.
Q: Is there a fast-track pathway for veterinary drugs?
A: Yes, MOA offers a priority evaluation and review pathway for: (1) innovative veterinary drugs with significant therapeutic advantages, (2) drugs targeting zoonotic diseases, (3) drugs urgently needed for animal disease prevention and control, and (4) drugs developed through international collaboration. Priority review can reduce the evaluation timeline by 30-50%.
Q: What are the GMP inspection requirements for overseas manufacturers?
A: MOA conducts on-site GMP inspections of overseas manufacturing facilities as part of the Class 5 registration process. The inspection covers the entire manufacturing process from raw material handling to finished product release. Some low-risk products may be eligible for remote inspection or document-based review. The GMP inspection must be passed before the registration certificate is issued.
Conclusion
Veterinary drug registration in China is a complex, time-intensive, and costly process — but for foreign pharmaceutical companies with the right products and a long-term commitment to the Chinese market, the rewards can be substantial. The key success factors are: early and continuous engagement with Chinese regulatory authorities, rigorous preparation of complete and accurate dossiers, investment in local clinical data generation, and partnership with experienced China-based regulatory and distribution partners. As China’s veterinary pharmaceutical regulatory framework continues to align more closely with international standards, the registration pathway is gradually becoming more predictable — but it remains one of the most demanding in the world. Companies that navigate this process successfully establish a significant competitive advantage in the world’s largest veterinary drug market.
